Investment Thesis
Disc Medicine is a pre-revenue biopharmaceutical company with substantial operating losses (-$69.5M) and significant quarterly cash burn (-$62.2M), providing approximately 14 quarters of runway at current burn rates. While the balance sheet is fortress-like with $688.4M equity and minimal debt, the deteriorating EPS (-51.8% YoY) and absence of revenue or near-term profitability visibility present fundamental weakness. Success depends entirely on clinical pipeline advancement, making this a speculative biotech investment without visibility into developmental stage or regulatory catalysts.
Strengths
- Fortress balance sheet with $688.4M stockholders equity and only $61.8M liabilities
- Minimal leverage with 0.04x debt-to-equity ratio and low financial distress risk
- Substantial asset base of $750.2M suggesting significant R&D investments and IP development
Risks
- No revenue generation - pre-commercial development stage with undefined monetization timeline
- Severe cash burn of $62.2M per quarter limits runway to ~14 quarters without additional capital
- Deteriorating EPS performance (-51.8% YoY) indicates accelerating losses and business challenges
- High regulatory and clinical risk inherent to pharmaceutical development; path to approval unclear
- Dependent on pipeline success with no visibility into clinical trial stage, efficacy, or regulatory status
Key Metrics to Watch
- Quarterly operating cash flow trend and cash runway sustainability
- Clinical trial progress, regulatory milestones, and FDA decision outcomes
- R&D spending allocation and pipeline advancement stage
Financial Metrics
Revenue
N/A
Net Income
-63.5M
EPS (Diluted)
$-1.65
Free Cash Flow
-62.2M
Total Assets
750.2M
Cash
88.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-9.2%
ROA
-8.5%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
24.00x
Quick Ratio
24.00x
Debt/Equity
0.04x
Debt/Assets
8.2%
Interest Coverage
-448.54x
Long-term Debt
29.4M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T10:45:56.864529 |
Data as of: 2026-03-31 |
Powered by Claude AI